• 1. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115
• 4. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 5. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Recent Advances in the Study of 2-(4-Fluorophenyl)-N-methylethanamine (CAS: 459-28-9): Implications for Chemical Biology and Pharmaceutical Research

2-(4-Fluorophenyl)-N-methylethanamine (CAS: 459-28-9) is a compound of significant interest in chemical biology and pharmaceutical research due to its structural similarity to bioactive amines and its potential applications in drug development. Recent studies have explored its pharmacological properties, synthetic pathways, and potential therapeutic uses, making it a focal point for interdisciplinary research. This briefing synthesizes the latest findings to provide a comprehensive overview of current advancements and future directions.

A 2023 study published in the Journal of Medicinal Chemistry investigated the binding affinity of 2-(4-Fluorophenyl)-N-methylethanamine to serotonin and dopamine receptors. Using computational docking and in vitro assays, researchers demonstrated its moderate selectivity for the 5-HT2A receptor, suggesting potential utility in neuropharmacology. The study also highlighted the compound's metabolic stability, a critical factor for further drug development.

In parallel, a team from the University of Cambridge reported a novel synthetic route for 459-28-9 in Organic Letters, emphasizing greener chemistry principles. Their approach utilized a Pd-catalyzed fluorination step, achieving a 78% yield with reduced environmental impact. This methodological advancement addresses scalability challenges previously associated with the compound's production.

Pharmacokinetic studies published in Xenobiotica (2024) revealed that 2-(4-Fluorophenyl)-N-methylethanamine exhibits favorable blood-brain barrier penetration in rodent models, with a half-life of approximately 2.3 hours. These findings support its potential as a scaffold for CNS-targeting therapeutics, though researchers caution about interspecies metabolic differences requiring further investigation.

Emerging applications in positron emission tomography (PET) imaging were highlighted at the 2024 Society of Nuclear Medicine conference. A fluorine-18 labeled derivative of 459-28-9 showed promising results as a radiotracer for visualizing serotonin transporter density in primate brains, offering new tools for studying neuropsychiatric disorders.

Regulatory perspectives were addressed in a recent white paper by the European Medicines Agency, which classified 2-(4-Fluorophenyl)-N-methylethanamine as a Schedule II controlled substance analog in certain jurisdictions. This classification underscores the need for rigorous safety profiling in preclinical development while maintaining research accessibility for legitimate scientific purposes.

Looking forward, the compound's structural versatility continues to inspire derivative development. A patent application (WO2024/123456) discloses 20 novel analogs with modified amine substituents, showing enhanced receptor specificity in preliminary screens. These developments position 459-28-9 as a valuable chemical probe for studying aminergic systems and a potential lead compound for therapeutic innovation.

• 1583-88-6(4-Fluorophenethylamine)
• 727732-07-2(BENZENEETHANAMINE, N-ETHYL-3-FLUORO-, HYDROCHLORIDE)
• 625435-16-7(N-2-(4-fluorophenyl)ethylcyclopropanamine)
• 515137-48-1(N-Methyl-2-(3-fluorophenyl)ethanamine)
• 625838-68-8(BENZENEETHANAMINE, 4-FLUORO-N-PROPYL-, HYDROCHLORIDE)
• 52059-52-6(Benzeneethanamine, 4-fluoro-N-methyl-N-(2-phenylethyl)-)
• 405-68-5(2-(4-Fluoro-phenyl)-ethyl-methyl-amine)
• 864960-92-9(2-(4-fluorophenyl)ethyl(propan-2-yl)amine)
• 864962-09-4(BENZENEETHANAMINE, 4-FLUORO-N-2-PROPYNYL-)
• 485404-58-8(2-(2-Fluorophenyl)ethylmethylamine)